Skip to Content

Vaprisol Approval History

  • FDA approved: Yes (First approved December 29th, 2005)
  • Brand name: Vaprisol
  • Generic name: conivaptan hydrochloride
  • Dosage form: Injection
  • Company: Astellas Pharma US, Inc.
  • Treatment for: Hyponatremia

Vaprisol (conivaptan hydrochloride injection) is an arginine vasopressin antagonist for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.

Development History and FDA Approval Process for Vaprisol

Oct 22, 2008Approval FDA Approves Astellas' Vaprisol (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Mar  2, 2007Approval FDA Approves Astellas' Vaprisol for the Treatment of Hypervolemic Hyponatremia
Dec 29, 2005Approval Vaprisol Astellas Pharma US, Inc. - Treatment for Euvolemic Hyponatremia
Dec  1, 2004FDA Issues Approvable Letter for Yamanouchi's Investigational Hyponatremia Treatment Conivaptan Hydrochloride Injection
Feb  2, 2004Yamanouchi Pharma America Submits New Drug Application to the FDA for Conivaptan Hydrochloride to treat Hyponatremia

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.